Valneva Tightens Belt as Travel Vaccine Revenue Falters, Banking on Lyme Shot to Reverse Fortunes

Valneva's Q1 revenue slumped to €30.9M, net loss €32.1M, but cash burn improved to €0.3M. Stock down 36% YTD; guidance cut, 10-15% job cuts. Focus on Pfizer-partnered Lyme vaccine LB6V.

The first-quarter numbers from Valneva tell two stories at once. Total revenue slumped to €30.9 million from €49.2 million a year earlier, and the net loss ballooned to €32.1 million. Yet the Austrian vaccine developer managed to slash its operational cash burn to just €0.3 million, a dramatic improvement from €8.1 million in the same period last year. That cash discipline, paired with a €37.0 million gross capital raise completed in April, left the company with €105.3 million in the bank as of March 31 — before the equity offering was even settled.

Investors, however, have focused on the top-line weakness. The stock ended last week at €2.47, more than 36% below its start to the year and well under the 50-day moving average of €2.90. The distance to the 52-week high stretches beyond 50%, and the shares are flirting with the support zone between €2.39 and €2.43. A break below the recent trough of €2.25 would open the door to further selling.

Travel vaccines take the blame

The revenue decline was concentrated in the travel vaccine portfolio. IXIARO/JESPECT sales fell to €20.2 million, DUKORAL contributed €8.6 million, and the newer chikungunya vaccine IXCHIQ managed only €1.6 million. Valneva attributed part of the drop to a deliberate reduction in third-party sales and uneven delivery timing to the U.S. Department of Defense, but also pointed to geopolitically driven demand weakness in key travel markets.

The deterioration forced management to revise its full-year product sales guidance downward. The new range of €135 million to €150 million replaces an earlier forecast of €145 million to €160 million — a cut that landed just days before the company’s appearance at the Bernstein European Small & Mid-Cap Conference in Nice on May 21.

A leaner cost base

In response, Valneva is accelerating its restructuring. The company will eliminate 10% to 15% of its global workforce, aiming to reduce operating costs by roughly one-third for the current year. The cutbacks are part of a broader effort to preserve cash while the commercial business struggles.

The capital raise that closed on May 5 added 15.9 million new shares, bringing the total outstanding count to approximately 189.8 million. The dilution has compounded the share price pressure, leaving existing holders with a smaller slice of a company that still needs to demonstrate it can generate sustainable revenue from its own products.

Pipeline as the only clear catalyst

With the commercial side under strain, all eyes are on LB6V, the Lyme borreliosis vaccine candidate formerly known as VLA15. Partner Pfizer is preparing regulatory filings after the Phase 3 VALOR study showed more than 70% efficacy in individuals aged five and older, with no safety signals identified. The program holds FDA Fast Track status and is the only late-stage Lyme vaccine in development globally — making it both Valneva’s strongest asset and its most binary risk.

Beyond LB6V, the company is also advancing its chikungunya vaccine in Brazil and working on a shigella candidate. But none of those near-term catalysts carry the same weight as the Lyme shot.

What’s next on the calendar

Investors will get two more chances to gauge sentiment in the coming weeks. Valneva is due to present at the Northern European Conference on Travel Medicine in Belfast from June 3 to 5, and the annual general meeting follows on June 25. The AGM is widely expected to draw pointed questions about the capital raise and the trimmed outlook.

Chart watchers note that a move above €2.60 would brighten the short-term picture, while resistance at €2.54 caps any immediate bounce. For now, the burden rests on Pfizer’s regulatory submissions to shift the narrative from cost-cutting to value creation.